Effect of β1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril
Autor: | Jeanette Strametz-Juranek, Richard Pacher, Barbara Sturm, Bernhard Frey, Brigitte Stanek, Rudolf Berger |
---|---|
Rok vydání: | 2000 |
Předmět: |
Male
medicine.medical_specialty Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Placebo Double-Blind Method Enalapril Internal medicine Humans Medicine cardiovascular diseases Heart Failure Ejection fraction Maintenance dose business.industry Patient Selection Dilated cardiomyopathy Middle Aged medicine.disease Atenolol Interim analysis Hospitalization Heart failure Anesthesia Disease Progression Cardiology Female Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | European Journal of Heart Failure. 2:407-412 |
ISSN: | 1388-9842 |
Popis: | Background The survival benefit of β-blocker treatment in patients with heart failure has been established in recent trials. Yet, the impact of β-blockers added on high dose angiotensin converting enzyme inhibitors has not been reported. Aims To investigate the effect of atenolol, a hydrophilic, selective β1-adrenergic antagonist, added on enalapril 40 mg/day in patients with advanced left ventricular dysfunction in a double-blind placebo-controlled trial. Methods One hundred and nineteen patients with class II or III heart failure, left ventricular ejection fraction ≤25% and treatment with 40 mg enalapril daily were given an initial challenge dose of atenolol 12.5 mg. One hundred patients (54 with idiopathic, 28 with ischemic, 18 with other dilated cardiomyopathy) tolerated challenge and were randomized to atenolol (maintenance dose 89±11 mg/day, range 50–100 mg/day) or placebo. The primary endpoint was combined worsening heart failure or death within 2 years, the secondary endpoint was hospitalization for cardiac events. Results After 395±266 days interim analysis revealed a significant difference between the atenolol and placebo group (log rank P |
Databáze: | OpenAIRE |
Externí odkaz: |